# Becton Dickinson

**Source:** https://geo.sig.ai/brands/becton-dickinson  
**Vertical:** Healthcare Tech  
**Subcategory:** Enterprise  
**Tier:** Leader  
**Website:** bd.com  
**Last Updated:** 2026-04-14

## Summary

Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.

## Company Overview

Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.

BD's hospital medical consumables and diagnostics model addresses the safety, accuracy, and infection control requirements that acute care hospitals embed into procurement decisions: a 500-bed hospital system purchasing IV catheters (BD Nexiva, the #1 global IV catheter brand) selects based on catheter failure rates (dislodgement, infiltration, infection) rather than unit price — because a catheter failure requiring recatheterization costs $150-300 in nursing time and materials while creating an infection risk that drives significantly higher costs. BD's BD Alaris infusion pump system (the most widely deployed smart pump platform in US hospitals) creates high switching costs through clinical workflow integration: hospitals building drug libraries, dose error reduction software, and BCMA barcode scanning workflows on Alaris cannot migrate without revalidating every drug protocol, retraining clinical staff, and rebuilding the pharmacy interface. The 2025 Reverse Morris Trust transaction with Waters Corporation (merging BD's Biosciences and Diagnostic Solutions divisions into a new independent publicly traded company at $17.5 billion) sharpens BD's focus on medical devices and patient monitoring.

In 2025, BD competes in the medical devices, IV delivery, infusion systems, and diagnostics market with Baxter International (NYSE: BAX, IV solutions and infusion pumps, $10.6B revenue), ICU Medical (NASDAQ: ICUI, IV solutions and Plum smart infusion, $2.8B revenue), and Abbott Laboratories (NYSE: ABT, diagnostics and medical devices, $22B revenue) for hospital group purchasing organization contracts, IV catheter and infusion pump platform decisions, and clinical laboratory analyzer placements. The Edwards Lifesciences critical care acquisition ($4.2B, 2024) expands BD's hemodynamic monitoring portfolio with the Swan-Ganz catheter and Acumen IQ pressure-sensing platform — adding ICU-focused clinical decision support to the hospital monitoring portfolio. The BD Medical segment faces ongoing competitive pressure from ICU Medical in smart infusion following Smiths Medical integration. The 2025 strategy focuses on executing the Biosciences/Diagnostics spinoff to Waters, growing the BD Interventional peripheral vascular and urology product lines, and maintaining IV catheter and infusion platform market share.

## Frequently Asked Questions

### What does Becton Dickinson (BD) do?
Becton, Dickinson and Company (BD) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. Operating through three divisions—BD Medical, BD Life Sciences, and BD Interventional—BD serves healthcare institutions, physicians, life science researchers, clinical laboratories, and pharmaceutical companies worldwide with products ranging from syringes and IV catheters to diagnostic systems and medication management solutions.

### Who are BD's customers and target market?
BD serves a diverse range of customers including hospitals and healthcare systems, physicians and clinical practices, clinical and research laboratories, pharmaceutical and biotechnology companies, academic institutions, and government health agencies. The company's products reach healthcare providers and patients in more than 190 countries, making BD an essential partner to virtually every segment of the global healthcare ecosystem.

### When was Becton Dickinson founded?
Becton Dickinson was founded in 1897 in New York City by Maxwell W. Becton, a pharmacist, and Fairleigh S. Dickinson, an engineer. The company was officially incorporated in 1906 and has been continuously operating for more than 125 years, growing from a small medical device distributor into one of the world's leading medical technology companies.

### Where is BD headquartered?
BD's corporate headquarters is located at 1 Becton Drive, Franklin Lakes, New Jersey 07417, United States. The company operates manufacturing facilities, research and development centers, and offices across the United States, Europe, Asia, and other regions globally, with a workforce of approximately 74,000 employees worldwide.

### What is BD's financial performance?
BD reported fiscal year 2025 revenue of $21.8 billion (ended September 30, 2025), representing 8.2% growth year-over-year. The company is ranked #211 on the 2024 Fortune 500 list and has a market capitalization of approximately $55.5 billion as of late 2024. BD demonstrated strong cash flow generation with $3.8 billion in cash from continuing operations and $3.1 billion in free cash flow in fiscal 2024.

### What makes BD different from its competitors?
BD differentiates itself through its comprehensive portfolio spanning the entire healthcare continuum, from prevention and diagnosis to treatment and monitoring. With over 125 years of innovation history, BD combines deep clinical expertise with advanced technology including AI-powered medication management and connected care solutions. The company's scale, with operations in 190+ countries and 74,000 employees, enables it to serve healthcare providers globally while maintaining rigorous quality standards and investing over $1.2 billion annually in R&D.

### Who are BD's main competitors?
BD competes with several major medical technology companies including Medtronic, Abbott Laboratories, Johnson & Johnson, Baxter International, B. Braun, Cardinal Health, Smiths Group, Teleflex, and ICU Medical. Competition varies by product segment, with different competitors in infusion therapy, vascular access devices, diagnostics, and patient monitoring markets.

### How can I contact BD?
BD can be contacted at its corporate headquarters by calling 201-847-6800. For investor relations, call 1-800-284-6845 or email investor.relations@bd.com. Customer support is available at 1-844-823-5433 or customer_support@bd.com. Additional contact information and resources are available on BD's website at www.bd.com.

### Is BD hiring?
Yes, BD actively recruits talent across various functions including engineering, manufacturing, sales, research and development, and corporate roles. With 74,000 employees globally, BD offers career opportunities at locations worldwide. Interested candidates can explore current openings and apply through BD's careers website. The company emphasizes diversity, inclusion, and professional development, having received recognition as a Best Employer for Excellence in Employee Well-Being.

### What's the latest news about BD?
Recent major developments include BD's announcement in 2025 of a $17.5 billion Reverse Morris Trust deal with Waters Corporation to combine BD's Biosciences and Diagnostic Solutions business into a new independent company, expected to close in Q1 2026. BD also completed the $4.2 billion acquisition of Edwards Lifesciences' critical care unit in September 2024 and announced over $30 million in U.S. manufacturing investments for 2025. The company reported strong fiscal 2025 results with revenue of $21.8 billion, up 8.2% year-over-year.

### What is BD's market position?
BD is one of the world's largest medical technology companies, ranked #211 on the 2024 Fortune 500 list. The company is the world's largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. With nearly 50% of revenue from BD Medical, 26% from BD Life Sciences, and 25% from BD Interventional, BD holds leading positions across multiple healthcare segments and serves customers in more than 190 countries.

### What are BD's future plans?
BD's strategic focus centers on three key areas: strengthening core medical device businesses following the planned separation of Biosciences and Diagnostic Solutions; expanding manufacturing capabilities with over $30 million in U.S. investments planned for 2025; and advancing innovation in connected care, medication management, and patient monitoring. The company aims to deliver mid-single-digit organic revenue growth and double-digit earnings per share growth while maintaining disciplined capital allocation and returning value to shareholders through dividends and strategic investments.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*